Zacks Research Has Optimistic Outlook of BHC Q2 Earnings

Bausch Health Cos Inc. (NYSE:BHC - Free Report) - Equities research analysts at Zacks Research lifted their Q2 2026 EPS estimates for shares of Bausch Health Cos in a report issued on Monday, June 23rd. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.98 for the quarter, up from their prior forecast of $0.97. The consensus estimate for Bausch Health Cos' current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos' Q3 2026 earnings at $1.14 EPS, FY2026 earnings at $4.12 EPS and Q1 2027 earnings at $1.10 EPS.

BHC has been the subject of several other research reports. Wall Street Zen downgraded Bausch Health Cos from a "buy" rating to a "hold" rating in a report on Saturday, May 10th. Royal Bank Of Canada raised their price target on Bausch Health Cos from $8.50 to $10.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. Based on data from MarketBeat.com, Bausch Health Cos currently has a consensus rating of "Hold" and a consensus target price of $7.42.

Bausch Health Cos Price Performance

Bausch Health Cos stock traded up $0.03 during mid-day trading on Thursday, hitting $6.44. 2,704,949 shares of the company's stock traded hands, compared to its average volume of 2,619,891. The firm has a 50 day simple moving average of $5.14 and a two-hundred day simple moving average of $6.27. Bausch Health Cos has a fifty-two week low of $3.96 and a fifty-two week high of $9.85. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -58.50 and a beta of 0.28.

Insider Transactions at Bausch Health Cos

In other news, Director John Paulson bought 3,564,059 shares of the company's stock in a transaction dated Friday, June 13th. The stock was bought at an average price of $5.94 per share, with a total value of $21,170,510.46. Following the completion of the acquisition, the director now owns 32,791,702 shares of the company's stock, valued at $194,782,709.88. This represents a 12.19% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders bought 6,352,667 shares of company stock valued at $35,870,767. 8.12% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bausch Health Cos

A number of hedge funds and other institutional investors have recently modified their holdings of BHC. Cary Street Partners Financial LLC bought a new position in shares of Bausch Health Cos in the first quarter worth $27,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Bausch Health Cos in the first quarter worth $27,000. SBI Securities Co. Ltd. increased its position in shares of Bausch Health Cos by 244.2% in the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after purchasing an additional 3,001 shares during the period. Mountain Hill Investment Partners Corp. bought a new position in shares of Bausch Health Cos in the fourth quarter worth $56,000. Finally, Wealthquest Corp bought a new position in shares of Bausch Health Cos in the first quarter worth $58,000. Institutional investors and hedge funds own 78.65% of the company's stock.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.